Is BPC-157 FDA-approved?
The short answer is no for consumer longevity or injury claims; verify any product-specific claim against official FDA records.
BPC-157, TB-500, KPV, MOTS-c, GHK-Cu, Semax, Epitalon, CJC-1295, Ipamorelin, Sermorelin and the messy line between approved medicine, compounding and research chemicals.
Readers seeing peptide claims from clinics, podcasts, forums or ads who want to separate regulatory status, evidence level and commercial hype.
The short answer is no for consumer longevity or injury claims; verify any product-specific claim against official FDA records.
BPC-157 has animal and mechanism-heavy discussion, but that is not the same as strong human injury evidence.
TB-500 is usually marketed as a peptide fragment related to thymosin beta-4, but naming can blur important evidence and quality questions.
Compounding can be lawful in some circumstances, but compounded drugs themselves are not FDA-approved products.
A regulatory review can affect what compounders, clinics and consumers can claim, but it does not create human efficacy evidence by itself.
Before benefit claims, readers should ask whether the substance is what the label says and whether it is appropriate for human use.
FDA
Jun 27, 2026
Peptide claims should be checked against official FDA compounding and approval resources before any clinical inference.
This is a regulatory signal, not efficacy evidence. It helps classify what a clinic or compounder may claim.
No. Some peptides have medical uses in specific contexts, while many longevity claims rely on early, indirect or non-human evidence.
No. Longevity Hacker News explains claims, evidence and boundaries; it does not provide personal instructions or sourcing guidance.